u/PossibleLack835

2 theses · first seen Jun 1, 2026

Window	Theses	Resolved	Wins	Win rate	Avg return	Median return
1d	1	1	0	0%	-9.1%	-9.1%
3d	1	1	0	0%	-9.4%	-9.4%
1w	2	2	1	50%	+3.0%	+3.0%
1m	2	2	1	50%	-7.9%	-7.9%
3m	2	2	0	0%	-24.3%	-24.3%
6m	1	1	0	0%	-20.0%	-20.0%
1y	0	0	0	—	—	—

Past performance does not predict future results. Informational only, not investment advice.

Thesis history

$TTDr/wallstreetbetsDDbullish

u/PossibleLack835 · 145d ago1 prior · 0% at 3mo

“250k in calls (position image unavailable for specific strike/expiry extraction)”

Why TTD will rally soon and I'm putting 250k in calls

TTD will rally driven by increased advertising spend from World Cup and midterm elections, combined with elevated short interest and technical support at $24 level. Author is allocating 250k to call options positioned for upside breakout.

At post $23.22Now $12.99-44.0% since postedas of Oct 23, 2:46 PM ET

1d-9.1%

3d-9.4%

1w-16.3%

1m-17.5%

3m-41.6%

6m—

1y—

original post →

$TNXPr/pennystocksDDbullish

u/PossibleLack835 · 330d ago1 prior · 0% at 3mo

TNXP is undervalued

Tonmya, the first FDA-approved fibromyalgia drug in 15 years, is projected to generate $49-130M annually with 1% market penetration and $219-365M by late 2026 at higher penetration. TNXP has $190M cash (exceeding market cap), profitability expected next year, and a $35M buyback with 20% short float positioning the stock for significant upside from current depressed levels.

At post $15.97Now $5.11-68.0% since postedas of Oct 23, 2:46 PM ET

1d—

3d—

1w+22.3%

1m+1.8%

3m-7.1%

6m-20.0%

1y—

original post →

End of results.